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social functioning of the patient, in some 
cases to an extent in which even after regres-
sion of symptoms the return to a normal 
social life is impossible. Moreover, DBS for 
TS seems to have significant incidence of 
complications and thus its indication must 
be evaluated adequately before proceeding 
(Servello, 2010). Conversely, drug treatment 
has been used when treating a young patient 
with a significant social impairment, but 
again, important adverse event may issue 
(Bestha, 2010).
Drug therapies involve antipsychotic 
medications that have been shown to be 
weighted by significant adverse effects 
that may persist during adulthood to a 
point that recently the need for more strict 
treatment guidelines has been required 
(Panagiotopoulos, 2010; Pringsheim and 
Pearce, 2010).
Considering the experiences presented 
in international literature, a structured 
protocol for drug therapies is usually not 
cited, and reports describe “maximum 
dose of established treatments” (Kuhn, 
2007), “an inadequate response to at least 
two dopamine blockers or catecholamine 
depletors” (Maciunas, 2007), “failure of best 
treatment by medication (antipsychotics), 
or intolerance after a minimum of 6 months 
of treatment” (Welter, 2008).
Indication to treatment be it invasive or 
conservative should be considered on the 
basis of a definition of refractoriness to 
treatments proposed in the previous “step” 
of the algorithm.
Our guideline is that patients need to 
be observed in order to document (1) the 
most impairing feature of that specific TS 
picture – this also helps when determining 
the appropriate target for DBS, and (2) the 
evolution of the clinical picture – and thus 
the need for an invasive treatment on the 
basis of the severity of clinical manifesta-
tions and the need for specific medications 
on the basis of clinical manifestations. At our 
Institution (IRCCS Galeazzi, Milan, Italy) 
patients are followed with at least 2 years 
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Gilles de la Tourette syndrome (TS) is a 
complex neuropsychological disorder 
usually characterized by both phonic and 
motor tics (Robertson, 2000; Porta et al., 
2009a,b). The prevalence of TS reaches 
50 per 10,000 in the general population 
(Leckman, 2002). Nevertheless, it is gen-
erally considered a “rare disease”: this 
is probably because of all the patients 
affected with TS only a minority suffers 
from a severe clinical picture. The syn-
drome demonstrates approximately a 
10-fold higher incidence in children than 
in adults (Leckman, 2002), with a preva-
lence of up to 299 per 10,000 in children 
of age 13–14 years (Mason, 1998), while 
the onset of tics occurs at a mean age 
of 5–7 years (Freeman, 2000; Leckman, 
2002). Especially because of this last 
issue, patients who are diagnosed with TS 
are often socially impaired. Even though 
the various degrees of severity of clinical 
manifestations of TS in certain cases allow 
a normal social functioning, when there 
is a social impairment this is often caused 
by tic manifestations. Tics are usually per-
ceived as inappropriate, mimicking com-
plex behaviors often of sexual nature. On 
the other hand, there is a widespread lack 
of information about TS so that people are 
unprepared to deal with these patients or 
to consider their behaviors as part of a dis-
ease. Moreover, behavioral comorbidities 
such as attention deficit-hyperactivity dis-
order (ADHD), obsessive–compulsive dis-
order (OCD), and depression can further 
complicate the picture, and patients may 
be socially hindered because of both tics 
and behavioral abnormalities. Considering 
the complexity of such a variable clini-
cal symptomatology in TS, the Tourette 
Syndrome Classification Study Group 
has introduced in their classification the 
subdivision between Definite Tourette 
Syndrome in which videotapes record the 
very clinical manifestations of the disease, 
and Tourette Syndrome by history, in 
which reliable caregivers (a family member 
or a close friend) documents and describes 
the clinical features of the disease (Tourette 
Study Group, 1993).
A further difficulty in defining the spe-
cific clinical picture for the patient is that 
tics may change during the course of ill-
ness and new tics can issue (Du, 2010; Liao, 
2010; Worbe, 2010). The development of 
diagnostic instruments that try to bypass 
the timing of the different clinical manifes-
tations, such as the Diagnostic Confidence 
Index (Robertson, 1999), demonstrate the 
need for a sound description of such an 
ever-changing clinical picture.
As previously said, in a significant num-
ber of cases TS patients present also behav-
ioral comorbidities. OCD is documented 
in up to 50% of patients in published 
experiences in Literature (Freeman, 2000; 
Robertson, 2000), while in our experience 
obsessive traits of personality can be dem-
onstrated in up to 85% of patients. ADHD is 
present in up to 60% of patients in our series 
and in patients series presented in literature 
(Freeman, 2000; Robertson, 2000). Anxiety 
is documented in up to 40% of patients in 
literature data (Freeman, 2000; Robertson, 
2000) while in our experience it presents 
in 50% of patients, while learning difficul-
ties during school age present in 30% of 
TS patients both in our experience and in 
literature data (Freeman, 2000; Robertson, 
2000). Some patients demonstrate a high 
grade of impairment in their social and 
working life (Neuner et al., 2009; Conelea, 
2010; Du, 2010; Eddy et al., 2010, 2011).
Considering that a significant percentage 
of these patients may show a certain degree 
of improvement up to a complete disap-
pearance of all clinical manifestations by the 
major age, deep brain stimulation (DBS) 
has classically been indicated for those 
patients failing to show a significant amel-
ioration of symptoms during adulthood 
(Mink, 2006). On the other hand, it is dur-
ing developmental age that clinical stigmata 
of the disorder cause the most of the dam-
age, severely, and permanently altering the 
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unsatisfying results (i.e., inadequate clini-
cal response and/or side effects) with at least 
two drugs belonging to these categories: (1) 
traditional and/or innovative antipsychotics, 
(2) catecolamine depletors, (3) SSRI.
When considering DBS, our main goal 
(Servello, 2008) is to put the patient’s qual-
ity of life at the base of a therapeutic algo-
rithm involving DBS.
Results of the DBS choice for these 
patients are at best still experimental, 
and thus a definitive indication to treat-
ment still has to be defined (Hariz and 
Robertson, 2010).
Ackermans (2008) reports different 
nuclei targeted with DBS for intractable 
TS: (1) the medial portion of the thalamus, 
at the cross point of centromedian nucleus 
(CM) with ventralis oralis pars intermedia 
(Voi); (2) the medial portion of thalamus, 
CM – parafascicularis (Pf); (3) the globus 
pallidus pars interna (GPi), posteroventro-
lateral part; (4) the GPi, anteromedial part; 
and (5) the nucleus accumbens (NAc) and 
anterior limb of internal capsule (IC).
A complete evaluation of the patient’s 
quality of life must include the main com-
plain of the patient and thus treatment 
should aim at treating that particular 
comorbidity or tic, and thus DBS target has 
to be tailored to the specific patient’s clinical 
manifestation (Sassi, 2010).
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